Tech Transfer Deals, July 2016: Kite Moves Toward Off-The-Shelf T-Cell Therapy

Kite licenses allogeneic cell technology from UCLA that may enable it to create off-the-shelf T-cell therapeutics, augmenting its ongoing development of autologous cancer therapies. See Scrip's monthly update on licensing agreements between companies and universities or other research institutions.